Thalidomide and immunomodulatory drugs as cancer therapy

Current Opinion in Oncology

Volumn 14, Issue 6, 2002, Pages 635-640

  Raje, Noopur ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOMODULATING AGENT; IRINOTECAN; PAMIDRONIC ACID; THALIDOMIDE; VINCRISTINE; DRUG DERIVATIVE; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; EVALUATION; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOMODULATION; KIDNEY CANCER; LUNG CANCER; MICROENVIRONMENT; MULTIPLE MYELOMA; MYELODYSPLASIA; NEUROPATHY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SOMNOLENCE; THROMBOSIS; BREAST TUMOR; COLON TUMOR; INFLAMMATION; KIDNEY TUMOR; LUNG TUMOR; MYELODYSPLASTIC SYNDROME;

ADJUVANTS, IMMUNOLOGIC; BREAST NEOPLASMS; CLINICAL TRIALS; COLONIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 0036855805     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200211000-00008     Document Type: Review

References (53)

1. Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565-1571.
2. Folkman J: Angiogenesis-dependent diseases. Semin Oncol 2001, 28:536-542.
3. Munshi NC, Wilson C: Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001, 28:565-569.
4. Salven P: Angiogenesis in lymphoproliferative disorders. Acta Haematol 2001, 106:184-189.
5. Di Raimondo F, Palumbo GA, Molica S, et al.: Angiogenesis in chronic myeloproliferative diseases. Acta Haematol 2001, 106:177-183.
6. Moehler TM, Neben K, Ho AD, et al.: Angiogenesis in hematologic malignancies. Ann Hematol 2001, 80:695-705. A comprehensive review of angiogenesis in hematologic cancer and therapeutic implications.
7. Stirling D: Thalidomide: A novel template for anticancer drugs. Semin Oncol 2001, 6:602-606.
8. Singhal S, Mehta J: Thalidomide in cancer. Biomed Pharmacother 2002, 56:4-12.
9. Richardson P, Hideshima T, Anderson K: Thalidomide: emerging role in cancer medicine. Annu Rev Med 2002, 53:629-657. A detailed review on the pharmacology and therapeutic applications of thalidomide in cancer.
10. Eriksson T, Bjorkman S, Hoglund P: Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001, 57:365-376.
11. Marriott JB, Muller G, Stirling D, et al.: Immunotherapeutic and antitumor potential of thalidomide analogues. Expert Opin Biol Ther 2001, 1:675-682.
12. Hideshima T, Chauhan D, Shima Y, et al.: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
13. Mitsiades N, Mitsiades CS, Poulaki V, et al.: Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications. Blood 2002, 99:4079-4086.
14. Mitsiades N, Mitsiades CS, Poulaki V, et al.: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002, 99:4525-4530.
15. Hideshima T, Chauhan D, Richardson P, et al.: NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277:16639-16647. An article highlighting the role of NFKB in myeloma pathogenesis, with therapeutic implications.
16. Hideshima T, Chauhan D, Schlossman R, et al.: The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene 2001, 20:4519-4527. An article highlighting the role of TNF-α in multiple myeloma pathogenesis.
17. Settles B, Stevenson A, Wilson K, et al.: Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol (Noisy-le-Grand) 2001, 47:1105-1114.
18. Majumdar S, Lamothe B, Aggarwal BB: Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002, 168:2644-2651.
19. Davies FE, Raje N, Hideshima T, et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
20. Podar K, Tai YT, Davies FE, et al.: Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001, 98:428-435.
21. Gupta D, Treon SP, Shima Y, et al.: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 2001, 15:1950-1961.
22. Lentzsch S, Rogers MS, LeBlanc R, et al.: S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 2002, 15:2300-2305.
23. D'Amato RJ, Lentzsch S, Anderson KC, et al.: Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol 2001, 28:597-601.
24. Hideshima T, Chauhan D, Podar K, et al.: Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001, 28:607-612. An excellent review highlighting novel treatment strategies in multiple myeloma.
25. Barlogie B, Desikan R, Eddlemon P, et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001, 98:492-494. An updated report with identification of prognostic factors in myeloma patients treated with single-agent thalidomide.
26. Barlogie B, Tricot G, Anaissie E: Thalidomide in the management of multiple myeloma. Semin Oncol 2001, 28:577-582.
27. Tosi P, Tura S: Antiangiogenic therapy in multiple myeloma. Acta Haematol 2001, 106:208-213.
28. Blade J, Esteve J, Rosinol L, et al.: Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol 2001, 28:588-592.
29. Neben K, Moehler T, Kraemer A, et al.: Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haemato1 2001, 115:605-608.
30. Neben K, Moehler T, Egerer G, et al.: High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 2001, 7:2675-2681.
31. Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M, et al.: The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol J 2002, 3:43-48.
32. Moehler TM, Neben K, Benner A, et al.: Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001, 98:3846-3848.
33. Ahmad I, Islam T, Chanan-Khan A, et al.: Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone Marrow Transplant 2002, 29:577-580.
34. Ciepluch H, Baran W, Hellmann A: Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Med Sci Monit 2002, 8:PI31-PI36.
35. Dimopoulos MA, Zervas K, Kouvatseas G, et al.: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001, 12:991-995.
36. Badros AZ, Siegel E, Bodenner D, et al.: Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 2002, 112:412-413.
37. Zangari M, Anaissie E, Barlogie B, et al.: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001, 98:1614-1615.
38. Dimopoulos MA, Zomas A, Viniou NA, et al.: Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 2001, 19:3596-3601.
39. Richardson PG, Schlossman RL, Weller E, et al.: Immunomodulatory derivative of thalidomide CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, in press. First reported clinical trial with the use of thalidomide analogues.
40. Steins MB, Padro T, Bieker R, et al.: Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002, 99:834-839.
41. Zorat F, Shetty V, Dutt D, et al.: The clinical and biologic effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 2001, 115:881-894.
42. Raza A, Meyer P, Dutt D, et al.: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98:958-965. A study with a large number of patients with myelodysplastic syndromes, demonstrating efficacy of thalidomide.
43. Zorat F, Pozzato G: Thalidomide in myelodysplastic syndromes. Biomed Pharmacother 2002, 56:20-30. An excellent review on the use of thalidomide in myelodysplastic syndromes.
44. Elliott MA, Mesa RA, Li CY, et al.: Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002, 117:288-296.
45. Canepa L, Ballerini F, Varaldo R, et al.: Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol 2001, 115:313-315.
46. Marx GM, Pavlakis N, McCowatt S, et al.: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2001, 54:31-38.
47. Motzer RJ, Berg W, Ginsberg M, et al.: Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002, 20:302-306.
48. Tseng JE, Glisson BS, Khuri FR, et al.: Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2001, 92:2364-2373.
49. Shepherd FA. Angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2001, 34 (suppl 3):S81-S89.
50. Figg WD, Arlen P, Gulley J, et al.: A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001, 28(suppl 15):62-66.
51. Stebbing J, Benson C, Eisen T, et al.: The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 2001, 85:953-958.
52. Nowak AK, Lake RA, Kindler HL, et al.: New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002, 29:82-96.
53. Zhou S, Kestell P, Tingle MD, et al.: Thalidomide in cancer treatment: A potential role in the elderly? Drugs Aging 2002, 19:85-100.